|
TJAP1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 7.81129605442743E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.1450996534611E-10 |
| Normal-vs-Stage2 |
4.0199000000074E-05 |
| Normal-vs-Stage3 |
1.25300000375361E-08 |
| Normal-vs-Stage4 |
4.22669999999847E-06 |
| Stage1-vs-Stage2 |
8.624000E-01 |
| Stage1-vs-Stage3 |
4.207200E-01 |
| Stage1-vs-Stage4 |
9.112400E-01 |
| Stage2-vs-Stage3 |
5.285600E-01 |
| Stage2-vs-Stage4 |
8.444800E-01 |
| Stage3-vs-Stage4 |
6.783400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.11989989398853E-10 |
| Normal-vs-AfricanAmerican |
5.516600E-03 |
| Normal-vs-Asian |
9.024600E-04 |
| Caucasian-vs-AfricanAmerican |
2.260200E-01 |
| Caucasian-vs-Asian |
4.167900E-02 |
| AfricanAmerican-vs-Asian |
7.824800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.13929999948581E-07 |
| Normal-vs-Female |
2.09130490702591E-11 |
| Male-vs-Female |
3.125000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.53840290401308E-11 |
| Normal-vs-Age(41-60Yrs) |
5.84139999704192E-08 |
| Normal-vs-Age(61-80Yrs) |
4.91510000477646E-08 |
| Normal-vs-Age(81-100Yrs) |
8.422300E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.848000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.258000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.826800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.071200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.807400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.112800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.85186999999143E-05 |
| Classical-VS-Follicular |
5.422500E-02 |
| Classical-VS-Other |
9.349800E-01 |
| Classical-VS-Normal |
1.43799999685612E-08 |
| Tall-VS-Follicular |
6.814000E-02 |
| Tall-VS-Other |
1.762590E-01 |
| Tall-VS-Normal |
1.34340316648718E-11 |
| Follicular-VS-Other |
5.885400E-01 |
| Follicular-VS-Normal |
1.76719999966934E-07 |
| Other-VS-Normal |
4.061700E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.21100000027852E-08 |
| Normal-vs-N1 |
1.91920000003343E-06 |
| N0-vs-N1 |
6.836600E-01 |
|
|
